Houston, TX (May 2020) – Pulmotect, Inc., a clinical-stage biotechnology company, has received approval from the U.S. Food & Drug Administration (FDA) to initiate two COVID-19 Phase-2 clinical trials of its innate immune-stimulating drug PUL-042. The Company plans to start accrual within the next week at up to twenty U.S. sites. The trials are for the prevention of infection with SARS-CoV-2 and the prevention of disease progression in patients with early COVID-19 disease. Funding for the trials came from the final closing of the Company’s offering of Series B Preferred stock in March.
SAN JOSE, Calif. (May 6, 2020 ) - Quartic.ai, a manufacturing AI and IIoT platform supplier, and Bright Path Laboratories, Inc. (Bright Path Labs), a provider of continuous flow reactor technologies, signed an agreement to develop an AI powered continuous manufacturing platform for active pharmaceutical ingredients (APIs) and other small molecule drugs using Bright Path Labs’ continuous bioreactor and the Quartic.ai smart manufacturing technology.
The most powerful names in AI and the global health community will join forces online Intelligent Health Inspired (25-27 May 2020).
At a time when collaboration globally is more important than ever; innovation must continue and healthcare and technology professionals must join forces to fight the biggest disruptor the world has faced in a generation, COVID-19.
Brussels, Belgium, May 05, 2020 – Univercells Technologies, a global provider of next-generation bioprocess technologies, launches today. Under this new brand, the company will focus on the commercialization of the product portfolio and will explore new technology developments to expand its position in the cell and gene therapy market.
London – On Tuesday, (12th May) CTS Virtual (https://arena-international.com/ctsvirtual/), will host new key sessions on Clinical Trial Supply 2020 Trends, Stem-gene Clinical Trials and many more.
As modern medicine advances, the global clinical supply chain needs to keep up, and the expanding market for stem-cell and gene therapy is making this increasingly complex for companies doing research and development in these areas. The therapeutic potential for stem-cell and gene products is vast, with targeted personalized medicine to suit the individual needs of sick patients, but running clinical supply operations in these fields can come at a high cost and requires detailed planning.